Phase 3 clinical trial results of an investigational drug has shown benefits in treating people with APOE4/4 with early ...

In a phase 2 trial, losartan treatment for 12 months was well tolerated but failed to reduce the rate of brain atrophy in patients with mild-to-moderate Alzheimer's disease (AD). The findings were ...

A new international study led by researchers at Karolinska Institutet demonstrates that it is possible to detect subtle ...

Alzheon, Inc., a clinical-stage biopharmaceutical company developing a broad portfolio of investigational therapies and diagnostic assays for patients with Alzheimer’s disease (AD) and other ...

The structural and functional organization of the brain as shown on MRI can predict the progression of brain atrophy in patients with early-stage, mild Parkinson's disease, according to a study ...

“There is a greater cognitive decline … a decline in mental ability, in being able to perform complex tasks.” Professor Gwenaëlle Douaud, lead author of the UK Biobank study reviewing the impact of ...

- Long-term, daily proprietary gamma sensory stimulation was shown to be safe and well tolerated; treatment integrated well into subjects' daily lives. - Pivotal trials will launch this year to ...